Cetuximab (Erbitux)

American Journal of Neuroradiology

Volumn 31, Issue 4, 2010, Pages 626-627

  Bou Assaly, W ^a,b   Mukherji, S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IRINOTECAN; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOPULMONARY ARREST; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MECHANISM; DRUG RECEPTOR BINDING; ECONOMIC ASPECT; HEAD AND NECK CANCER; HUMAN; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG EMBOLISM; METASTASIS; RADIATION DERMATITIS; SEPSIS; SINGLE DRUG DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; COLORECTAL NEOPLASMS; DRUG APPROVAL; DRUG COSTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; OTORHINOLARYNGOLOGIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77950817535     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A2054     Document Type: Article

References (14)

1. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007;67:2585-2607
2. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005;27:684-694
3. Steiner P, Joynes C, Bassi R, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007;13:1540-1545 (Pubitemid 46450446)
4. Martinelli E, De Palma R, Orditura M,et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1-9
5. Erbitux (Cetuximab); [package insert]. New York and Princeton, New Jersey: ImClone Systems and Bristol-Myers Squibb; 2009
6. Ettinger DS. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 2009 Sep 25. [Epub ahead of print]
7. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59(2 suppl):21-26
8. Pérez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67
9. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-1048 Epub 2009 Jun 29
10. Koukourakis MI, Tsoutsou PG, Karpouzis A, et al. Radiochemotherapywith cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2009 Sep 8. [Epub ahead of print]
11. Birnbaum A, Dipetrillo T, Rathore R, et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol 2009 Sep 25. [Epub ahead of print]
12. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008;11:791-799 Epub 2008 Jan 11
13. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009; 101:1182-1192 Epub 2009 Aug 7
14. Holmer AF. Cetuximab in colon cancer. N Engl J Med 2004;351:1575-1576